GLMD - Latest News

Galmed Pharmaceuticals Ltd. (GLMD), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $2.8M. Beta to the broader market is 0.74.

The article list below shows the most recent GLMD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent GLMD Headlines

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

prnewswire.com - Jul 16, 2026

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penet

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

prnewswire.com - Jun 22, 2026

Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

prnewswire.com - Jun 8, 2026

Transaction will add FDA Breakthrough Device-Designated technology with active U. S.

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

prnewswire.com - Jun 2, 2026

- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing di

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

prnewswire.com - May 14, 2026

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical ba

How News Affects GLMD Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track GLMD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked GLMD news questions

What is the latest GLMD news headline?

The most recent GLMD headline (Jul 16, 2026) is "Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the GLMD news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What GLMD news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual GLMD options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.